13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Statins-Lipodomics

    Acronym: 

    ACTRN/NCT /ethics: 

    ACTRN12617000965303

    Scientific title: 

    A multi-centre, open-label trial of simvastatin in addition to docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Clinical Trials - Phase Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Male Anticipated Start Date 2018-05-01
    Molecular Target Anticipated End Date 2019-09-30
    Cancer Type Prostate
    Trial Type Treatment
    Phase Clinical Trials - Phase
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2018-05-01
    Anticipated End Date 2019-09-30

    Trial Summary

    This study aims to aims to test whether treatment with simvastatin during docetaxel chemotherapy for metastatic castration-resistant prostate cancer can reverse a poor prognostic plasma lipid signature. All study participants will be treated with simvastatin 40mg daily (oral tablet) for 12 weeks, at the same time as starting docetaxel chemotherapy. All participants will be followed up for 12 weeks to monitor safety and to assess the lipid profile using plasma samples. It is hoped that this study will help answer the question of whether a 12 week course of a lipid-lowering drug called simvastatin (commonly used to treat high cholesterol, heart disease and diabetes) will lower the specific circulating lipids in blood that are associated with a worse prognosis in metastatic castration-resistant prostate cancer.

    Lay Summary

    A multi-centre, open-label trial of simvastatin in addition to docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

    Sponsor / Cooperative group

    Chris O'Brien Lifehouse

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting